Clinical trial · Interventional
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial
NCT01233544CI-TRIAL-00022112RAS01terminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient recruitment
Summary
Brief summary (as posted)
This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases. Primary end point is local progression free survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Carcinoma | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Metastases | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SBRT or RFA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Stereotactic body radiation therapy
- description
- Colorectal liver metastases treated by SBRT
- interventionNames
- Procedure: SBRT or RFA
- type
- ACTIVE_COMPARATOR
- label
- Radiofrequency ablation
- description
- Colorectal liver metastases treated by RFA
- interventionNames
- Procedure: SBRT or RFA
Primary outcomes (1)
- measure
- Local progression-free survival
- timeFrame
- 3 years
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Adenocarcinoma of the colon or rectum * Liver metastases * Inoperable (technical or medical) * 1-4 metastases * Maximum 40 mm in diameter * Suitable for both therapies, RFA and SBRT Exclusion Criteria: * Uncontrolled extrahepatic disease and uncontrolled primary cancer * Liver cirrhosis
References
Publications (0)
Data not yet available
No reference posted for this study.